Thomson Reuters Injects Drug Data into Eikon
The app allows researchers to identify drug pipelines and companies' exposure to particular areas.
Dubbed Healthcare Intelligence, the app uses content from Thomson Reuters' Cortellis life sciences data platform to provide a "one-stop location" for existing and in-development pharmaceuticals, and was developed in response to client demand for access to consolidated information from different sources to make it easier to identify a company's existing presence and R&D pipeline for particular drugs or diseases.
The vendor's Cortellis platform covers more than 61,000 drugs under development and
Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.
To access these options, along with all other subscription benefits, please contact info@waterstechnology.com or view our subscription options here: http://subscriptions.waterstechnology.com/subscribe
You are currently unable to print this content. Please contact info@waterstechnology.com to find out more.
You are currently unable to copy this content. Please contact info@waterstechnology.com to find out more.
Copyright Infopro Digital Limited. All rights reserved.
As outlined in our terms and conditions, https://www.infopro-digital.com/terms-and-conditions/subscriptions/ (point 2.4), printing is limited to a single copy.
If you would like to purchase additional rights please email info@waterstechnology.com
Copyright Infopro Digital Limited. All rights reserved.
You may share this content using our article tools. As outlined in our terms and conditions, https://www.infopro-digital.com/terms-and-conditions/subscriptions/ (clause 2.4), an Authorised User may only make one copy of the materials for their own personal use. You must also comply with the restrictions in clause 2.5.
If you would like to purchase additional rights please email info@waterstechnology.com
More on Data Management
FactSet-LiquidityBook: The buy-side OMS space continues to shrink
Waters Wrap: Anthony spoke with buy-side firms and industry experts to get a feel for how the market is reacting to this latest tie-up.
S&P sees strong demand for GenAI tools as leadership changes hands
The data provider released several AI-enabled tools and augmentations to existing platforms in 2024 and plans to continue to capitalize on the technology in 2025.
To modernize loan markets, making data more accessible is key
Wilmington Trust is using AccessFintech’s Synergy platform to ditch faxes and emails in the increasingly popular asset class.
Lucrative market data deal with LSEG fuels Tradeweb’s record quarter
The fixed-income trading venue realized gains from its 2023 deal with the London Stock Exchange Group, amid soaring revenues from market data providers industry-wide.
Is overnight equities trading a fad or the future?
Competition is heating up in US equity markets as more venues look to provide trading from twilight to dawn. But overnight trading has skeptics, and there are technical considerations to address.
DTCC revamps data distribution, collection efforts with cloud, AI
The US clearinghouse is evaluating the possibilities that cloud and AI offer to streamline the processes by which it collects and makes data available to market participants.
European exchange data prices surge, new study shows
The report analyzed market data prices and fee structures from 2017 to 2024 and found that fee schedules have increased exponentially. Several exchanges say the findings are misleading.
We’re running out of datacenters! (But maybe AI can help?)
The IMD Wrap: Datacenter and cloud adoption is being pushed to its limits by AI. Will we simply run out of space and power building AIs before AI figures out how to fix it?
